tiprankstipranks
Trending News
More News >
Hyperion Defi, Inc. (HYPD)
:HYPD
US Market

Hyperion DeFi (HYPD) Price & Analysis

Compare
947 Followers

HYPD Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Merger And CollaborationThe proposed merger of topical ophthalmic platforms could present the next constructive chapter for Optejet and broader development.
Product DevelopmentCollaborations in dry eye disease development are seen as upside, with the user-filled Optejet potentially defining the most realistic shot for near-term progress.
Technology And InnovationEyenovia’s Optejet ophthalmic spray device is already FDA approved for Mydcombi, which is used for induced pupil dilation for eye exams and related surgery.
Bears Say
Clinical Trial FailuresThe Phase 3 CHAPERONE trial using the Optejet optimized spray dispenser for delivering MicroPine atropine for reduction of pediatric progressive myopia was discontinued.
Market RisksRisks to the investment thesis include failure of products and/or candidates to achieve peak commercial revenue estimates due to market size, penetration rates, and/or pricing.

HYPD FAQ

What was Hyperion Defi, Inc.’s price range in the past 12 months?
Hyperion Defi, Inc. lowest stock price was $0.85 and its highest was $124.80 in the past 12 months.
    What is Hyperion Defi, Inc.’s market cap?
    Hyperion Defi, Inc.’s market cap is $32.81M.
      When is Hyperion Defi, Inc.’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Hyperion Defi, Inc.’s earnings last quarter?
      Currently, no data Available
      Is Hyperion Defi, Inc. overvalued?
      According to Wall Street analysts Hyperion Defi, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Hyperion Defi, Inc. pay dividends?
        Hyperion Defi, Inc. does not currently pay dividends.
        What is Hyperion Defi, Inc.’s EPS estimate?
        Hyperion Defi, Inc.’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Hyperion Defi, Inc. have?
        Hyperion Defi, Inc. has 2,882,808 shares outstanding.
          What happened to Hyperion Defi, Inc.’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Hyperion Defi, Inc.?
          Currently, no hedge funds are holding shares in HYPD

          Hyperion DeFi Stock Smart Score

          Company Description

          Hyperion Defi, Inc.

          Eyenovia, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing transformative ophthalmic therapies. The company operates in the biotechnology and pharmaceuticals sectors, with a core focus on creating microdosed medications for eye care using its proprietary Optejet dispenser. Eyenovia's pipeline includes therapies for myopia progression, presbyopia, and pupil dilation.
          Similar Stocks
          Company
          Price & Change
          Follow
          Matinas BioPharma
          Enveric Biosciences
          Galecto
          Popular Stocks
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis